News und Analysen

A clutch of post-earnings price target increases by analysts helped raise Medtronic's (NYSE: MDT) stock at a healthy rate on Wednesday. The sturdy medical device specialist's shares rose by almost

Premier (NASDAQ:PINC), a leading provider of healthcare supply chain and performance improvement solutions, reported its fiscal fourth-quarter results on August 20, 2025, for the period ended June

The average healthcare stock has a yield of just 1.8%, which isn't much to write home about today. You can do much better than that with Medtronic (NYSE: MDT), currently yielding 3%, or if you're

Shares of health insurer UnitedHealth Group (NYSE: UNH) received a boost last week after investors learned that Warren Buffett's company, Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B), has invested

What the stock analysis community giveth, it can also taketh away.

That was the dynamic behind the slide of UnitedHealth Group (NYSE: UNH) stock on Tuesday. As in the previous trading session, the

Medtronic (NYSE: MDT) stock had declined 3.6% through 2:45 p.m. ET Tuesday despite beating forecasts for fiscal 2026 first-quarter earnings this morning.

Heading into the report, analysts predicted

Premier(NASDAQ:PINC) reported fourth quarter and full-year 2025 results on August 19, 2025, with revenue of $986 million and adjusted EPS of $1.54, both exceeding guidance. The company’s Supply

Medtronic (NYSE:MDT), a global medical technology leader specializing in cardiovascular, neuroscience, and surgical devices, reported Q1 FY2026 earnings on August 19, 2025. The most notable news

UnitedHealth Group (NYSE: UNH) has been a staple in the healthcare world for decades and is one of the largest companies in the world, with a market cap of around $280 billion as of Aug. 18

UnitedHealth Group (NYSE: UNH), by far the health insurance stock that's gotten most of the market's attention over the past few trading sessions, had a good Monday on the exchange. Its shares added

Despite President Donald Trump's trade wars and concerns about a possible recession, equity markets have performed relatively well this year, with the S&P 500 (SNPINDEX: ^GSPC) up 10% since January

UnitedHealth Group (NYSE: UNH) has been a solid dividend growth stock for years. Generally, its yield has been fairly low, due to the stock's rising value. Even as the healthcare insurance giant has

PAVmed (NASDAQ:PAVM), a medical technology innovator focused on minimally invasive diagnostics and digital health devices, published its earnings results on August 14, 2025. The headline news was a

Accuray reported fourth-quarter fiscal 2025 results on August 13, 2025, with $128 million in revenue (down 5% year-over-year), service revenue of $56.9 million (up 4% year-over-year), and adjusted

The market has abandoned UnitedHealth Group (NYSE: UNH), and that's exactly why I'm buying it. While investors flee the stock over rising medical costs and regulatory headlines, they're missing a

Novo Nordisk (NYSE: NVO) and UnitedHealth (NYSE: UNH) have seen their share prices fall in recent weeks.

*Stock prices used were the afternoon prices of Aug. 11, 2025. The video was published on

Medtronic (NYSE: MDT) isn't getting much love on Wall Street today. The stock has fallen around 33% since hitting a peak in mid-2021. That's a huge decline, but it may be overdone. Sure, there are

People have sung Fleetwood Mac's lyrics for decades: "Don't stop thinking about tomorrow." But investors might want to focus on a different timeline.

No one knows what tomorrow holds. At least with

UnitedHealth (NYSE: UNH) stock was proving to be beneficial for investors' financial health on Hump Day. They were trading the big health insurance company's stock up by nearly 4% in late-session

Pulse Biosciences (NASDAQ:PLSE), a medical device innovator focused on nanosecond pulsed field ablation (nsPFA) for treating various conditions, released its second-quarter 2025 results on August

RadNet (NASDAQ:RDNT) reported its Q2 2025 results on Aug. 11, 2025, posting record revenue of $498.2 million, up 8.4% year-over-year and record adjusted EBITDA (non-GAAP) of $81.2 million, up 12.3%

Harvard Bioscience (NASDAQ:HBIO), a provider of specialized laboratory technologies for biomedical and life sciences research, released its financial results for the second quarter of fiscal 2025 on

RadNet (NASDAQ:RDNT), a major operator of outpatient diagnostic imaging centers, published its second quarter 2025 results on August 11, 2025. The company reported record revenue of $498.2 million